Aflac Incorporated (NYSE:AFL) Shares Sold by Achmea Investment Management B.V.

Achmea Investment Management B.V. reduced its stake in Aflac Incorporated (NYSE:AFL) by 4.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 295,646 shares of the financial services provider’s stock after selling 12,743 shares during the quarter. Achmea Investment Management B.V.’s holdings in Aflac were worth $30,581,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AFL. Franklin Resources Inc. increased its stake in Aflac by 75.2% during the 3rd quarter. Franklin Resources Inc. now owns 776,131 shares of the financial services provider’s stock worth $88,533,000 after buying an additional 333,083 shares during the period. Aptus Capital Advisors LLC boosted its stake in Aflac by 79.7% during the 3rd quarter. Aptus Capital Advisors LLC now owns 27,354 shares of the financial services provider’s stock worth $3,058,000 after purchasing an additional 12,131 shares during the period. Transamerica Financial Advisors Inc. acquired a new stake in Aflac during the 3rd quarter worth $979,000. Roxbury Financial LLC acquired a new stake in shares of Aflac in the 4th quarter worth $948,000. Finally, FMR LLC lifted its stake in shares of Aflac by 4.0% in the 3rd quarter. FMR LLC now owns 1,202,104 shares of the financial services provider’s stock worth $134,395,000 after acquiring an additional 45,745 shares during the period. 67.44% of the stock is currently owned by institutional investors and hedge funds.

Aflac Stock Performance

Aflac stock opened at $104.67 on Thursday. The stock has a 50-day simple moving average of $105.24 and a 200 day simple moving average of $107.70. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $57.21 billion, a price-to-earnings ratio of 10.90, a P/E/G ratio of 3.24 and a beta of 0.93. Aflac Incorporated has a 12-month low of $79.31 and a 12-month high of $115.50.

Aflac (NYSE:AFL) last announced its quarterly earnings data on Wednesday, February 5th. The financial services provider reported $1.56 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. On average, research analysts anticipate that Aflac Incorporated will post 6.88 earnings per share for the current fiscal year.

Insider Transactions at Aflac

In related news, EVP Audrey B. Tillman sold 24,744 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $103.40, for a total value of $2,558,529.60. Following the completion of the transaction, the executive vice president now directly owns 222,618 shares in the company, valued at approximately $23,018,701.20. The trade was a 10.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph L. Moskowitz sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the director now owns 25,393 shares of the company’s stock, valued at $2,733,048.59. This represents a 3.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,546 shares of company stock worth $5,863,616. 0.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of Aflac from $98.00 to $105.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Barclays reduced their price target on shares of Aflac from $98.00 to $95.00 and set an “underweight” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. lifted their price target on shares of Aflac from $90.00 to $94.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Wells Fargo & Company lowered their target price on shares of Aflac from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 19th. Finally, Keefe, Bruyette & Woods reduced their price target on shares of Aflac from $107.00 to $104.00 and set a “market perform” rating for the company in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $103.36.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.